Pharmacokinetics and safety of arginine supplementation in animals.

Pharmacokinetics and safety of arginine supplementation in animals. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacokinetics and safety of arginine supplementation in animals. Abstract Text:

Guoyao Wu,Fuller W Bazer,Timothy A Cudd,Wenjuan S Jobgen,Sung Woo Kim,Arantzatzu Lassala,Peng Li,James H Matis,Cynthia J Meininger,Thomas E Spencer,

Anticipating the future use of arginine to enhance fetal and neonatal growth as well as to treat diabetes and obesity, we performed studies in pigs, rats, and sheep to determine the pharmacokinetics of orally or i.v. administered arginine and the safety of its chronic supplementation. Our results indicate that all 3 species rapidly catabolized the supplemental arginine. The elevated circulating concentrations of arginine generally returned to baseline levels within 4-5 h after administration, with the rates varying with the age and physiological status of the animals. The clearance of arginine was greater in pregnant than in nonpregnant animals, in young than in adult animals, in lean than in obese animals, and in type-1 diabetic than in nondiabetic animals. I.v. administration of arginine-HCl to pregnant ewes (at least 0.081 g arginine.kg body weight-1.d-1) did not result in any undesirable treatment-related effect. Neonatal pigs, growing-finishing pigs, pregnant pigs, and adult rats tolerated large amounts of chronic supplemental arginine (e.g. 0.62, 0.32, 0.21, and 2.14 g.kg body weight-1.d-1, respectively) administered via enteral diets without the appearance of any adverse effect. On the basis of the comparative studies and a consideration of species differences in food intake per kilogram body weight, we estimate that a 70-kg human subject should be able to tolerate long-term parenteral and enteral supplemental doses of 6 and 15 g/d arginine, respectively, in addition to a basal amount of arginine (4-6 g/d) from regular diets.

Pharmacokinetics and safety of arginine supplementation in animals. Publishing Authors By Initials

G Wu,FW Bazer,TA Cudd,WS Jobgen,SW Kim,A Lassala,P Li,JH Matis,CJ Meininger,TE Spencer,

For similar animals: chordata: vertebrates: mammals: artiodactyla: swine: sus scrofa research abstracts see: animals: chordata: vertebrates: mammals: artiodactyla: swine: sus scrofa research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacokinetics and safety of arginine supplementation in animals. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: The Journal of nutrition

VOLUME: 137

Page Numbers: 1673S-1680S

Journal Abbreviation: J. Nutr.

ISSN: 0022-3166

DAY: 3

MONTH: Jun

YEAR: 2007

Pharmacokinetics and safety of arginine supplementation in animals. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 404243

Pharmacokinetics and safety of arginine supplementation in animals. Keywords Mesh Terms:

KEYWORDS: Sus scrofa

MESH TERMS: metabolism

Chemical & Substance for Abstract: Pharmacokinetics and safety of arginine supplementation in animals. Information

Substance Name: Arginine

Registry Number: 74-79-3

Grant and Affiliation Information for Pharmacokinetics and safety of arginine supplementation in animals.

AFFILIATION: Department of Animal Science, Texas A&M University, College Station, TX 77843, USA. g-wu@tamu.edu

Country: United States

AGENCY: United States NIEHS

GRANT: 5P30ES09106

ACRONYM: ES

MEDLINETA: J Nutr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacokinetics and safety of arginine supplementation in animals Related Publications

• Abuse of the disabled child: a systematic review of population-based studies.
• Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
• Bioinformatic prediction of polymerase elements in the rotavirus VP1 protein.
• Biosynthesis of butirosin: transfer and deprotection of the unique amino acid side chain.
• Calibration algorithm for eyetracking with unrestricted head movement.
• Carving up space at imaginary joints: can people mentally impose arbitrary spatial category boundaries?
• Characterization of photopolymerization of dentin adhesives as a function of light source and irradiance.
• Cholesterol surrogates incorporating a benzophenone as part of the sterol tetracycle.
• Differential responses of hypothalamus-pituitary-adrenal axis immediate early genes to corticosterone and circadian drive.
• Effects of formalin fixation and collagen cross-linking on T2 and magnetization transfer in bovine nasal cartilage.
• Fuzzy clustering of Raman spectral imaging data with a wavelet-based noise-reduction approach.
• Hypomagnesaemia in cystic fibrosis patients referred for lung transplant assessment.
• Identification of putative in vivo substrates of calpain 3 by comparative proteomics of overexpressing transgenic and nontransgenic mice.
• Introduction: ethics committees and failure to thrive.
• Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.
• Mixed amphetamine salts extended release for the treatment of ADHD in adolescents: current evidence.
• Nonsteroidal benzophenone-containing analogues of cholesterol.
• Pharmacokinetics and safety of arginine supplementation in animals.
• Planning "discrete" movements using a continuous system: insights from a dynamic field theory of movement preparation.
• Pregnancy and interferon tau regulate RSAD2 and IFIH1 expression in the ovine uterus.
• Progesterone regulation of preimplantation conceptus growth and galectin 15 (LGALS15) in the ovine uterus.
• Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation.
• Restorative service trends in private general practice in Australia: 1983-1999.
• Short-term cardiovascular effects of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder.
• Synthesis of benzophenone-containing fatty acids.
• The cytomegalovirus homolog of interleukin-10 requires phosphatidylinositol 3-kinase activity for inhibition of cytokine synthesis in monocytes.
• The energy dependence syndrome.
• The intracellular genistein metabolite 5,7,3',4'-tetrahydroxyisoflavone mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway.
• WNTs in the ovine uterus: potential regulation of periimplantation ovine conceptus development.
• Worsening of quality of life after epilepsy surgery: effect of seizures and memory decline.